Highlights:
• BTC statutory profit after tax of $4.9m (1H FY24: $1.7m)
• BTC and investee companies consolidated 1H FY25 performance:
• revenue up 9% to $5.3m (1H FY24: $4.9m)
• gross profit up 6% to $2.3m (1H FY24: $2.2m)
• operating expenses remain well controlled at $2.1m (1H FY24: $2.1m)
• EBITDA of $0.2m (1H FY24: $0.1m)
• net cash reserves of $2.7m (1H FY24: $2.4m)
• Investee businesses greatly diversified and strengthened with:
• acquisition of the Corcym heart valve business – adding $3.6m revenue per annum
• award of a $5m 5-year ECMO contract with Royal Childrens’ Hospital - Melbourne
• Rhythmic and Elasto-Q infusion pumps approved for private health reimbursement
• Bronchitol and Aridol license for Aus/NZ extended indefinitely
Executive Chairman and Managing Director Dr Richard Treagus commented, "We have significantly strengthened and diversified the business over the last 6 months, and with a solid foundation established, we are well positioned to continue the positive momentum throughout 2025.”
READ THE FULL ANNOUNCEMENT HERE
READ THE INVESTOR PRESENTATION HERE
About us:
About BTC Health
BTC Health is a registered Pooled Development Fund and has investments in three core medical companies:
- BTC Speciality Health, which is responsible for the commercialisation and distribution of medical devices and medical consumables in the therapeutic categories of acute pain management and neurospinal surgery.
- BTC Pharma, which undertakes the registration, development, sales and marketing of specialised pharmaceutical medicines, that serve niche markets and rare diseases.
- BTC Cardio, which is dedicated to the marketing and distribution of highly specialised cardiovascular medical equipment and single-use consumable products used by cardiac surgeons and critical care experts.
Contact details:
For more information, please contact:
BTC Health Limited (ASX:BTC)
Dr Richard Treagus
Executive Director
T: +61 417 520 509
E: rtreagus@btchealth.com.au
Tracy Weimar
Company Secretary
T: +61 3 9692 7222
E: tracy.weimar@vistra.com
Investor Relations
The Capital Network
Julia Maguire
T: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au